Background Ticlopidine, an antiplatelet agent, when compared with aspirin has been found to reduce the risk of stroke in high-risk patients, ie, those with recent transient ischemic attack, reversible ischemic neurological deficit, amaurosis fugax, or minor stroke. Its cost-effectiveness in such use, however, is unknown.
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To the best of our knowledge, however, no formal assessment of the costs, risks, and benefits of ticlopidine therapy has been reported. In this study, we therefore examined the cost-effectiveness of ticlopidine relative to aspirin in the prevention of stroke in high-risk patients. We used techniques of decision analysis to address the following four related questions: (1) What would be the difference in lifetime incidence of initial stroke between patients receiving ticlopidine versus aspirin? (2) What would be the resulting difference in life expectancy? (3) How would expected lifetime costs of medical treatment compare between these therapies? and (4) How does the cost-effectiveness of ticlopidine compare with that of other generally accepted medical interventions?
Methods

Overview of the Model
To estimate the cost-effectiveness of ticlopidine in preventing stroke in high-risk patients, we developed a decisionanalytic model in which a hypothetical cohort of 100 men and women with recent TIA, reversible ischemic neurological deficit, amaurosis fugax, or minor stroke was assumed to receive either ticlopidine (500 mg daily) or aspirin (1300 mg daily, the currently approved dose for this indication in the United States) (Figure) . For convenience, we assumed that all patients would be 65 years of age (the average age of persons with these cerebrovascular events) when therapy was initiated. 3 We then estimated and compared the expected incidence of stroke, life expectancy, and expected lifetime medical care costs according to treatment. Since both stroke and side effects of therapy may cause health-related quality of life to decline, we used utility weights to adjust expected years of life for disease-and treatment-related morbidity. 5 -6 In our model, we evaluated outcomes and costs monthly to age 100 years. In each month, we assumed that patients may experience an initial fatal or nonfatal stroke and that those who do not Model of monthly outcomes of primary stroke prevention.
may die of other causes. Ticlopidine and aspirin were assumed to reduce stroke incidence but possibly cause side effects that require treatment. Because the value of long-term therapy with aspirin or ticlopidine is unknown, we assumed that all such treatment would be stopped after 5 years, the duration of follow-up in TASS, 3 after which stroke risk would revert to untreated levels. We also assumed that patients who experience nonfatal stroke would have therapy discontinued.
Once estimated, our model yields life expectancies (unadjusted and adjusted for changes in quality of life) for patients receiving ticlopidine and aspirin based on the sum of the probabilities (divided by 12) of surviving to each future month. It also yields lifetime medical care costs, which we assumed to consist of the costs of stroke prevention, stroke treatment, and ongoing medical care for noncerebrovascular diseases. We calculated the cost-effectiveness of ticlopidine versus aspirin as the ratio of the estimated difference (ticlopidine minus aspirin) in expected lifetime medical care costs to the corresponding difference in quality-adjusted life expectancy. Because the utility of life after stroke is unknown, we allowed the assumed value to vary. We examined the sensitivity of our results to changes in a number of key model parameters.
We evaluated all benefits and costs from a societal perspective (ie, regardless of payer) and adjusted all costs to 1991 average price levels using the medical care component of the Consumer Price Index for All Urban Consumers (CPI-U) (Bureau of Labor Statistics, unpublished data, 1991). We discounted all future benefits and costs at an annual rate of 5%.
All probabilities and costs employed in the model are reported in Tables 1 and 2 . Model calculations were performed using SMLTREE version 2.9 decision analysis software (Jim Hollenberg, MD, January 1989).
Side Effects of Therapy
We estimated the incidence of side effects associated with ticlopidine and aspirin therapies based on the number of adverse experiences reported in TASS. 3 In this trial, 1518 patients received ticlopidine (500 mg daily) and 1527 patients received aspirin (1300 mg daily), and they were followed up for an average of 40 months. Adverse experiences were reported in 945 patients (62.3%) who received ticlopidine and 813 (53.2%) who received aspirin. Two of these reported events, neutropenia and gastrointestinal hemorrhage, were assumed to be potentially serious, possibly requiring hospitalization or resulting in death. All other adverse events, including diarrhea, dyspepsia, rash, and minor bleeding disorders, were assumed to be minor in nature.
In TASS, neutropenia (ANC of <1200/mm 3 ) was experienced by a total of 35 patients who received ticlopidine and none who received aspirin. We therefore assumed in our model that 2.3% (ie, 35/1518) of the patients receiving ticlopidine would develop this complication. Although only one patient with neutropenia in TASS developed a systemic infection, 3 we assumed conservatively that 10% of the neutropenic patients would be hospitalized for septicemia and that 26% of these hospitalized cases would be fatal, based on the rate reported for patients with sepsis. 7 All other patients with neutropenia were assumed to be treated on an outpatient basis. A variety of other less serious side effects, including diarrhea, dyspepsia, nausea, rash, and minor bleeding disorders, such as purpura and epistaxis, were assumed to occur among patients receiving either therapy. We estimated the proportions of patients experiencing these events to be 59.5% and 57.8% for ticlopidine and aspirin, respectively, by deducting the rates of neutropenia and gastrointestinal hemorrhage from the overall proportions of patients in TASS with any reported adverse experience.
Since most reported cases of neutropenia in TASS occurred early in the course of therapy, we assumed for convenience in our model that all such events would occur during the first 3 months of treatment. We assumed that other side effects would occur at a constant monthly rate during therapy, which we estimated by dividing the total incidence of these events by the average number of months that patients received medication in TASS (ie, 25.9 and 28.6 months for ticlopidine and aspirin, respectively).
We assumed that all patients who experience neutropenia or gastrointestinal bleeding would discontinue therapy. We further assumed that one third of patients who experienced a minor side effect would discontinue therapy, based on the number of patients in TASS who discontinued therapy due to side effects. relative risk of stroke among persons with TTA compared with the general population. 8 ' 9 Because stroke risk is highest in the months immediately after TLA. and declines thereafter, we used separate estimates of relative risk for the first and all subsequent years (16.5 and 7.0, respectively). 9 The resulting estimates of stroke incidence were then divided by 12 to yield monthly rates.
We assumed that patients who receive aspirin would experience a 15% decline in stroke risk relative to these untreated rates, based on the largest placebo-controlled trial of aspirin therapy in patients with TIA. 10 We further assumed that patients who receive ticlopidine would experience a 21% risk reduction relative to aspirin, based on results reported from TASS. 3 For patients who discontinue therapy, either because of side effects or at the end of 5 years, we assumed that stroke risk would revert to untreated levels.
Mortality
We estimated the proportion of strokes that would be fatal using age-specific case-fatality rates reported in Rochester, Minn, during 1980 through 1984. 7 To estimate mortality among high-risk patients who do not experience stroke, we estimated the ratio of nonstroke mortality for persons with cerebrovascular disease to that for the general population, and then multiplied this ratio by actuarial mortality rates for the US population. First, to estimate nonstroke mortality among stroke survivors, we subtracted mortality due to recurrent stroke (ie, the rate of recurrence times the case-fatality rate) from total mortality after nonfatal atherothrombotic brain infarction in the Framingham Heart Study." We then expressed this as a ratio to the age-adjusted rate of all-cause mortality among all persons in the Framingham population. Finally, we multiplied this ratio by mortality rates obtained from Social Security life tables 12 ; these data were used because standard US life tables do not report mortality for persons over the age of 85 years.
We used Framingham data similarly to estimate mortality after an initial nonfatal stroke. We first calculated the ratio of total mortality after nonfatal atherothrombotic brain infarction to that in the general Framingham population, and then multiplied this ratio by actuarial mortality rates. 11 ' assigned a utility weight equal to unity. Those who die were assigned a utility weight of 0. Patients who have a nonfatal stroke were assigned a utility weight ranging from 0.75 to 0.95 for the remainder of their lives. We also assigned decrements in utility for the states of acute illness in our model. Acute stroke and side effects requiring hospitalization were assumed to diminish utility by 0.50 during the months in which these events occur, and side effects treated in an outpatient setting were assumed to cause a one-month decrement of 0.05.
Costs of Therapy
The costs of ticlopidine and aspirin therapies were assumed to include medication, laboratory tests, and the treatment of side effects. We estimated the daily cost of ticlopidine (two 250-mg pills) and aspirin (four 325-mg enteric-coated pills) therapy to be $2.75 and 13 cents, respectively, based on an informal survey of retail prices of several Boston-area pharmacies. We assumed that all patients who receive ticlopidine would also incur the costs of biweekly complete blood counts during the first 3 months of therapy at an estimated $18 per test, based on average Medicare charges (Health Care Financing Administration, unpublished data, 1987); such testing is recommended in the package literature. 4 Hospitalizations for gastrointestinal hemorrhage and systemic infections resulting from neutropenia were estimated to cost $4997 and $8028, respectively, based on average Medicare reimbursements for diagnosis-related groups [DRGs] 174 (gastrointestinal hemorrhage with complications or comorbidities) and 416 (septicemia, age greater than 17). 13 We estimated the cost of related inpatient professional services to be $356 for gastrointestinal hemorrhage and $486 for septicemia, based on the Medicare fee schedule for physicians' services. 14 These costs reflect average lengths of stay of 7.0 days for gastrointestinal hemorrhage and 11.2 days for septicemia, 15 during which the patient is assumed to receive an initial hospital visit (Health Care Financing Administration Common Procedure Coding System [HCPCS] 99223) by an internist at a cost of $117, daily visits (HCPCS 99231) thereafter at $31, and discharge services (HCPCS 99238) at $53. 14 We assumed that patients who experience less severe gastrointestinal bleeding would be treated on an outpatient basis at a total cost of $48, including $30 for an office visit (HCPCS 99213) and $18 for a complete blood count.
14 Patients with neutropenia who are not hospitalized were assumed to incur total treatment costs of $96, comprising two office visits and two complete blood counts.
We assumed that all other side effects would entail on average one additional office visit at a cost of $30.
Costs of Stroke Treatment
For patients who experience stroke, we accounted for the costs of the initial event as well as ongoing costs of stroke treatment during the remainder of their lives.
We assumed that all patients who experience an initial stroke would incur costs of inpatient care, including hospital and professional services. We estimated hospital costs to be $6399, based on the average Medicare reimbursement for DRG 14 (specific cerebrovascular disorders except TIA). 13 Inpatient professional fees were estimated at $627, based on an average length of stay of 11.0 days during which patients were assumed to receive an initial hospital visit (HCPCS 99223) by an internist costing $117, daily follow-up visits (HCPCS 99231) at a rate of $31, discharge services (HCPCS 99238) costing $53, and a consultation (HCPCS 99255) with a neurologist at a cost of $147. 14 - 15 We estimated that 6.8% of patients with nonfatal strokes would receive inpatient rehabilitation services after their discharge from acute care, based on the proportion of Medicare patients in DRG 14 who received such services within 60 days of discharge from the hospital during 1984 through 1985. 16 Patients admitted to a rehabilitation unit for poststroke care were estimated to incur a cost of $40 793 17 ; this cost was assigned to the month following the initial stroke.
During the remainder of their lives, stroke survivors were assumed to incur related costs of nursing home care, outpatient visits to physicians and other professional providers (eg, physical therapists and speech therapists), home health care, and inpatient acute and rehabilitation care for recurrent strokes.
We estimated that in any given month, 2.2% of stroke survivors aged 65 through 74 years would reside in nursing homes because of stroke and that this proportion would increase to 8.2% and 19.1%, respectively, among those aged 75 through 84 years and 85 years and older. These rates were estimated by dividing age-specific numbers of nursing home residents in the United States with a primary diagnosis of stroke at admission, estimated from the 1985 National Nursing Home Survey (National Center for Health Statistics, unpublished data, 1988), by the total age-specific prevalence of stroke in the United States, based on data from the 1985 National Health Interview Survey (National Center for Health Statistics, unpublished data, 1986). We estimated the average monthly cost of nursing home care to be $2385, based on reported mean charges for residents with a primary diagnosis of stroke in the 1985 National Nursing Home Survey.
We estimated the average monthly cost of stroke-related outpatient and home health care, including physician visits, other professional services, and the purchase or rental of aids and appliances, to be $101, based on data reported in the National Survey of Stroke. 18 Finally, we estimated the expected monthly cost of acute recurrent stroke to be $52, based on the average annual rate of recurrence in Framingham (6.6%) n and average costs of inpatient acute and rehabilitation care assumed equal to those of initial strokes.
Cost of Ongoing Medical Care for Noncerebrovascular Diseases
We assumed that the costs of care for noncerebrovascular diseases among patients who remain alive would be comparable with those of the general population, which we estimated to be $574 per month. This estimate was obtained by deducting the proportion of personal health-care expenditures among men and women aged 65 years and older that represent treatment of stroke from 1987 US personal health-care expenditures in this age group, and expressing the result as a monthly rate. 19 ' 20 
Sensitivity Analysis
We examined the sensitivity of our results to changes in number of model parameters, including the difference in risk of stroke between ticlopidine-and aspirin-treated patients, the risk of neutropenia for patients receiving ticlopidine, the risk of gastrointestinal hemorrhage for patients receiving aspirin, and the rate of discount. We also examined how our results would change if treatment with ticlopidine and aspirin were continued for a lifetime rather than terminated at 5 years. In the latter analysis, we assumed that the reduction in stroke risk for patients receiving aspirin would persist and that patients receiving ticlopidine would have, alternatively, an unchanged risk of stroke relative to aspirin (ie, continuing benefit) or a level of risk after 5 years similar to that of patients receiving aspirin (ie, no additional benefit). All sensitivity analyses were conducted with the utility of life after initial stroke at the midpoint of its assumed range (ie, 0.85).
Results
The Incidence of Stroke
Among a cohort of 100 high-risk patients aged 65 years, 46 and 44 patients who receive aspirin and ticlopidine, respectively, are estimated to experience initial strokes during their lifetimes. Ticlopidine therapy therefore is projected to reduce the number of initial strokes by two.
Life Expectancy
Average life expectancy (undiscounted) among patients who receive aspirin would be 10.71 years compared with 10.76 years among those treated with ticlopidine, an increase of approximately one-half month.
Quality-adjusted life expectancy among aspirintreated patients ranges from 9.93 to 10.53 (discounted, 7.18 to 7.54) years, as the utility of life after initial stroke is assumed to range from 0.75 to 0.95. For patients receiving ticlopidine, quality-adjusted life expectancy similarly ranges from 10.04 to 10.60 (discounted, 7.25 to 7.58) years.
The Costs of Stroke Prevention and Treatment
Costs of aspirin therapy over 5 years (discounted) are expected to be $135 per patient, compared with $2939 for ticlopidine. Costs of treatment for side effects of aspirin and ticlopidine are expected to be $76 and $66, respectively.
Lifetime costs of stroke treatment among patients who receive aspirin are expected to be $9219, compared with $8539 for ticlopidine. Costs of ongoing medical care for noncerebrovascular diseases are expected to be $52 672 and $52 899 for patients who receive aspirin and ticlopidine, respectively.
Overall, lifetime medical care costs of patients who receive ticlopidine are expected to exceed those of patients who receive aspirin by $2341 ($64 443 versus $62 102).
The Cost-effectiveness of Ticlopidine Compared With Aspirin
The cost-effectiveness of ticlopidine relative to aspirin ranges from $31 200 to $55 500 per quality-adjusted life-year gained, as the utility of life after initial stroke is assumed to vary from 0.75 to 0.95. At the midpoint of this range, cost per quality-adjusted year of life gained is $39 900.
Sensitivity Analysis
We varied the reduction in risk of stroke among ticlopidine-treated patients across its reported 95% confidence interval (4% to 38%). 3 At the lower limit of efficacy, the cost-effectiveness of ticlopidine is $306 000 per quality-adjusted year of life gained, and at the upper limit this ratio is $18 300.
We varied the risk of neutropenia for patients treated with ticlopidine from one half to twice our base-case assumption. At one half of our base-case estimate of risk, cost-effectiveness is $38 300 per quality-adjusted year of life gained. If the incidence of neutropenia is doubled, cost-effectiveness is $43 800.
Since low doses of aspirin (325 mg per day or less) have been reported to reduce the risk of bleeding complications without compromising the effectiveness of antiplatelet therapy, we examined how the costeffectiveness of ticlopidine would change if aspirintreated patients were assumed to have no risk of gastrointestinal hemorrhage. Under this assumption, ticlopidine costs $44 700 per quality-adjusted year of life gained.
We varied the annual rate of discount we used from 2% to 8%. Using a 2% discount rate, cost-effectiveness is $33 800 per quality-adjusted year of life gained, and at an 8% rate this ratio is $46 300.
Finally, we examined how the cost-effectiveness of ticlopidine would change if treatment were continued for a lifetime, assuming alternatively continuing benefit and no additional benefit after 5 years compared with aspirin. Assuming continuing benefit, the cost-effectiveness of ticlopidine is $42 000 per quality-adjusted year of life gained. Alternatively, assuming no additional benefit after 5 years, this ratio is estimated to be $57 500.
Discussion
We used a decision-analytic model and published clinical and epidemiologic data to examine the costeffectiveness of ticlopidine versus aspirin therapy in preventing stroke in high-risk patients. Our findings indicate that patients who receive ticlopidine would experience two fewer initial strokes per hundred than those treated with aspirin. The cost-effectiveness of ticlopidine is estimated to range from $31 000 to $55 000 per quality-adjusted life-year gained, as poststroke utility is assumed to range from 0.75 to 0.95. These results compare favorably with those reported for other generally accepted medical interventions to prevent or treat cardiovascular disease. 21 -23 The results of our study are particularly interesting in light of the US Food and Drug Administration's recommendation that ticlopidine be reserved for aspirinintolerant patients where aspirin is indicated to prevent stroke. While this decision may reflect concern about the risk of neutropenia, our findings suggest that this may be outweighed by ticlopidine's greater efficacy compared with aspirin. Even after accounting for morbidity and mortality due to neutropenia, we found life expectancy (unadjusted as well as quality adjusted) to be longer for patients receiving ticlopidine than for those who were assumed to receive aspirin.
The cost-effectiveness of ticlopidine varies substantially according to the value (ie, utility) that is assigned to nonfatal strokes that are prevented. Although there is growing interest in incorporating the utilities of health states into medical-economic evaluations, these have been reported for relatively few diseases and not for stroke. 5 In a previous study of the risks and benefits of carotid endarterectomy, life after major and minor strokes was assumed to have utilities of 0.2 and 0.8, respectively. dine of $71 000 -more than 25% higher than the result obtained when nonfatal stroke is assumed to result in only a 0.05 decrement in utility. Without quality adjustment, one assigns no value to the prevention of nonfatal strokes, which are five times as frequent as fatal ones in these patients. While the precise decrement in utility arising from nonfatal stroke is uncertain, failure to account for some loss in quality of life may cause the cost-effectiveness of stroke prevention to be seriously understated.
We estimated the reduction in stroke risk among patients receiving ticlopidine using intention-to-treat results from TASS, which reflect outcomes for patients who discontinued therapy prematurely as well as those who did not. In our model, however, we conservatively assigned this risk reduction only to patients who continue to be treated; patients who discontinued therapy were assumed to derive no further benefit. We therefore may have understated the benefit of ticlopidine therapy. In TASS, ticlopidine in fact reduced stroke risk by 24% over 5 years (compared with aspirin) among patients who continued treatment. 4 Use of this estimate in our model instead of the assumed value (ie, 21%) would have improved cost-effectiveness by about 15%, to $34 000 per quality-adjusted year of life gained, assuming poststroke utility of 0.85.
Some methodological limitations of our study should also be noted. For one, we estimated stroke risk after TIA using population data from Rochester, Minn. The generalizability of these data to other populations is uncertain. Stroke incidence in Rochester during 1975 through 1979 was substantially lower than that reported in the National Survey of Stroke for the same period. 818 If stroke incidence is in fact lower in Rochester than nationally, we again may have underestimated the benefits of stroke prevention and also ticlopidine's cost-effectiveness.
Our analysis was based heavily on the results of a single trial (ie, TASS) involving 3000 high-risk patients who were followed up for 5 years. 3 Although the generalizability of trial data to other patient populations and longer periods of therapy is uncertain, we note that the outcomes observed among both aspirin-and ticlopidine-treated patients in this study are similar to those observed in other trials of these agents in cerebrovascular disease. 2533 We also assumed that treatment would be terminated after 5 years, since the efficacy of ticlopidine therapy of longer duration has not been documented. We recognize, however, that clinicians are unlikely to terminate therapy in practice. In a sensitivity analysis, we found that the cost-effectiveness of ticlopidine remains essentially unchanged (ie, approximately $40 000 per qualityadjusted year of life gained, assuming poststroke utility is 0.85) if therapy is assumed to continue for a lifetime with no diminution in benefit after 5 years. If the level of benefit diminishes after 5 years, cost-effectiveness would correspondingly decline; in the extreme case, involving zero benefit after 5 years, cost per qualityadjusted year of life gained increases by about 40% (ie, to $57 000).
Our estimates of the costs of stroke treatment are based in part on the rate of stroke recurrence reported in the Framingham Heart Study and levels of utilization of outpatient and home health services reported in the National Survey of Stroke. 1017 The generalizability of these data is uncertain, however. Framingham data, for instance, cover the years 1949 through 1975, and improved control of cardiovascular risk factors may have since diminished the risk of recurrence.
11 - 34 On the other hand, the rise in per capita expenditures on outpatient and home health care among the elderly since the mid-1970s, when the National Survey of Stroke was conducted, has significantly outpaced the rate of inflation. 35 Finally, we estimated overall expected outcomes and costs of ticlopidine therapy among patients aged 65 years at intervention, without regard to gender. Patients in TASS, on which our model was based, ranged in age from 39 to 94 (mean, 63 years), and 65% were men. Although the reduction in stroke risk for ticlopidine was reported to be greater among women (27%) than men (19%), this difference was not statistically significant. The relation of age to efficacy was not examined. 3 How the cost-effectiveness of ticlopidine varies by age and gender hence remains uncertain.
In conclusion, the use of ticlopidine to prevent stroke in high-risk patients appears to be cost-effective by current standards of medical treatment. Our study therefore suggests that ticlopidine may have an important role in clinical practice.
